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1. Introduction
  Malaria, particularly due to Plasmodium falciparum 
(P. falciparum) is a leading cause of disease and death 
worldwide. Approximately 5% of the World’s population 
is at risk and an estimated 225 million confirmed cases 
and 781 000 deaths have been reported in 2009[1]. The 
emergence and spread of multidrug-resistant P. falciparum, 
particularly to the previous mainstay antimalarial drugs 
chloroquine (CQ), and sulphadoxine-pyrimethamine (SP) is 
further worsening the situation. To deal with the resistance 
of P. falciparum, World Health Organization (WHO) now 
advocates artemisinin combination therapies (ACTs) as the 
first-line treatment for uncomplicated falciparum malaria 
in all malaria endemic areas[2]. Replacing ineffective, 
failing treatments (CQ and SP) with ACTs the morbidity and 
mortality associated with malaria has been reduced[3-5].
  In India, about 2 million cases of malaria are reported 
annually and till 2009 CQ was the first line treatment for P. 
falciparum. Resistance to CQ was first reported in 1973 from 
Diphu area of Karbi Anglong district of Assam[6] and then 
has spread in various parts of the country[7-9]. Therapeutic 
efficacy studies done in India between 1978 and 2007 
documented a failure to chloroquine beyond cut off level of 
10%[10]. In an effort to counteract the increasing resistance of 
P. falciparum to CQ National Vector Borne Disease Control 
Programme has recently introduced ACT, a combination 
of artesunate + sulphadoxine-pyrymethamine (AS + SP), 
as the first line agent for the treatment of uncomplicated 
P. falciparum malaria throughout India. Among the other 
combinations of ACTs, artemether + lumefantrine (AM+LF), 
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not included in the National Drug Policy, but licensed for 
marketing in India is in frequent use by private practitioners.
  Although artemisinin and its derivatives are the most potent 
and rapidly acting antimalarials, its resistance has been 
reported in murine models of malaria[11]. More recently, in 
vivo and in vitro artemisinin resistance has been documented 
among human falciparum malaria infections in South East 
Asia[12,13]. A recent in vivo randomized, three-arm open 
label prospective trial of ACTs by Calcutta School of Tropical 
Medicine in Jalpaiguri district of West Bengal, India has 
showed a therapeutic failure of 9.5% and 4.1% in AS+SP and 
AM+LF study arms respectively (unpublished data). Studies 
provide compelling evidences that artemisinins act by 
selectively inhibiting PfATPase6 protein, the only SERCA-
type Ca2+-ATPase in the P. falciparum genome, believed to 
be the primary target for artemisinins[14,15]. A subsequent 
study in French Guyana showed that S769N PfATPase6 
mutation was associated with raised artemether IC50, and 
suggested that the mutation may be used as a molecular 
marker for monitoring artemisinin resistance[16]. The present 
study was aimed to evaluate the in vivo therapeutic efficacy 
of two commonly used combinations of ACTs i.e. AS+SP and 
AM+LF and to investigate the polymorphism at codon S769N 
of the PfATPase6 gene among P. falciparum field isolates 
collected from Kolkata, India.
2. Materials and methods
2.1. Study site and design
  The study was carried out at the Malaria Clinic attached 
to the Department of Protozoology of the Calcutta School 
of Tropical Medicine, Kolkata, India from October, 2010 to 
February, 2011, where the annual parasite index in 2008 was 
10.69. In Kolkata, malaria transmission is seasonal (July-
December) with predominance of falciparum malaria.
The study was a randomized, two-arm open label 
prospective tr ial ,  for  evaluation of  cl inical  and 
parasitological responses of two ACTs (AS+SP and AM+LF) 
for treatment of uncomplicated P. falciparum malaria, based 
on the therapeutic efficacy protocols of WHO[17]. The study 
protocol was approved by the Institutional Ethics Committee 
of the Calcutta School of Tropical Medicine.
2.2. Screening and enrolment of patients
  The febrile patients from the surrounding areas attending 
the Malaria Clinic of the Calcutta School of Tropical 
Medicine were screened for malarial parasite by examining 
Giemsa stained thick and thin peripheral blood smears. 
All patients with confirmed P. falciparum mono-infection 
were explained about the study protocol and requested to 
participate in the study. Those who fulfilled the following 
inclusion criteria as per WHO protocol[17] were enrolled after 
obtaining written, informed consent. 
  All patients with confirmed P. falciparum infection 
(asexual parasites 1 000-100 000/ 毺L), with fever (axillary 
temperature ≥37.5 曟) or history of fever in preceding 24 h 
and fulfilling other inclusion criteria were explained about 
the benefits and risks of the study. Pregnant or lactating 
mother and children under 5 kg bodyweight were excluded. 
Patients with other febrile conditions, danger signs[17] or 
severe malaria were also excluded. Recruited patients were 
randomized into two study groups by using “Simple Random 
Sampling without Replacement”. 
2.3. Treatment of enrolled patients
  The therapeutic efficacy of two different regimens of ACTs 
was evaluated in the present study. The tested ACTs were 
AS+SP, AM+LF. AS and SP were supplied by NVBDCP, 
AM+LF were procured from M/S Themis Medicare Limited, 
India. All the patients were treated as per WHO guidelines[2] 
for the treatment of Malaria according to their body weight. 
In AS+SP group, artesunate 4 mg/kg body weight once daily 
for 3 days and a single dose of SP (25/1.25 mg base/kg body 
weight) on day 0 were administered. In AM+LF group (a co-
formulated tablets containing 20 mg of artemether and 120 mg
of lumefantrine), a total of six doses were administered at 0, 
8, 24, 36, 48, and 60 hours. The number of tablets per dose 
according to body weight; one tablet for 10-15 kg, two tablets 
for 15-25 kg, three for 25-35 kg and four for those weighing 
over 35 kg. Primaquine (PQ) 0.75mg/Kg single dose was given 
on day 1. Study team directly observed and documented 
administration of each dose of medication.
2.4. Follow up and study endpoints
  The day, the patient was enrolled and received the first 
dose of medicine was designated as day 0. Thereafter, the 
schedule calls for clinical re-assessment were done on 
day 1, 2, 3, 7, 14, 21, 28, 35 & 42. Patients were advised to 
return on any day during follow-up period if symptoms 
recurred without waiting for schedule visit day. During the 
follow-up visits the axillary temperature was recorded. In 
addition, thorough clinical examination was carried out 
to identify the presence of any danger signs of severe and 
complicated malaria. On the event of occurrence of any 
such complications  the patient was withdrawn from the 
study and was treated as per existing standard of care for 
that condition. Blood was collected in EDTA vial on day 0 
and any other day on reappearance of parasite for molecular 
biology studies. 
  According to the WHO 42-day follow-up protocol[17] for 
assessment and monitoring of antimalarial drug efficacy 
for the treatment of uncomplicated falciparum malaria, 
the follow-up completed patients met one of the following 
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clinical endpoints: (1) early treatment failure, (2) late 
treatment failure, which included late clinical failure and 
late parasitological failure and (3) adequate clinical and 
parasitological response .
2.5. Statistical analysis
  The data was entered into a standard data entry programme 
designed by Global Malaria Programme and analyzed by 
Kaplan-Meier survival curve according to WHO standard 
procedures (http://www.who.int/malaria/resistance). 
Statistical software “R” (version 2.13.1) was used to calculate 
the Z-test value for the comparison of the efficacy of 
the two study arms and the 95% confidence interval was 
calculated by Dimension Research calculator (http://www.
dimensionresearch.com/resources/resources overview.html). 
2.6. Laboratory examination
2.6.1. Microscopy and parasite count
  Parasite counts were done on Giemsa-stained thick films 
and the number of parasites per 200 WBC was counted, 
assuming a WBC count to be 8 000/毺L, parasitaemia was 
calculated and expressed as per 毺L of blood. A thick smear 
was diagnosed as negative on initial review if no parasites 
were seen in 100 oil immersion fields and 10% of positive 
and negative slides were crosschecked. Females in child 
bearing age group were subjected to human chorionic 
gonadotropin test (TestPack® +Plus™ hCG Urine, Abbott, 
USA).
2.6.2. DNA extraction and PCR genotyping
  Genomic DNA of P. falciparum was isolated from 200 毺L
EDTA blood us ing  QiaAmp DNA miniki t  as  per 
manufacturer’s instructions (Qiagen, Hilden, Germany). 
Isolated DNA was stored at -20 曟 and an aliquot was used 
as the DNA source for molecular biological study. 
  The recrudescence and re-infection of P. falciparum 
was differentiated by using msp 1 (block 2), msp 2 (block 
3) marker genes. The polymorphic repetitive regions of 
these genes were amplified by nested PCR using the 
oligonucleotide primers, as described elsewhere[18,19]. All 
amplification reactions were carried out in a final volume 
of 20 毺L which included 2 毺L of DNA template (genomic 
DNA for the primary reactions and the product of the primary 
reaction for the secondary amplification). Oligonucleotide 
primers were used at final concentrations of 0.3 毺M in 
both primary as well as secondary reactions. The reaction 
mixture contained PCR Buffer, 0.2 mM concentration of each 
of the four deoxynucleoside triphosphates, and 0.75 U of 
AmpliTaq polymerase (Perkin Elmer, Branchburg, NJ, USA). 
The reactions were carried out in the presence of 2 mM 
MgCl2 for all oligonucleotide combinations except the msp 2 
nested PCR, for which a concentration of 1.5 mM MgCl2 was 
used. Amplification was performed using a Veriti 96 well 
Thermal Cycler (Perkin Elmer, Branchburg, NJ, USA) under 
the following conditions: an initial denaturation at 94 曟 for 
2 min followed by 30 cycles of denaturation at 94 曟 for 30 s, 
annealing at 54 曟 for primary PCR (50 曟 for msp 2 nested 
and 59 曟 for msp 1 nested) for 1 minute, extension at 72 曟 
for 2 min. The final extension was done at 72 曟 for 5 min. 
The PCR products were stored at 4 曟 until further analysis 
was done.
  Nested PCR products were analyzed by electrophoresis 
using 2% agarose gels (performed in TBE buffer). All the 
distinguishable allelic variants for each marker paired 
samples were loaded side by side. The gels were stained with 
Ethidium Bromide and visualized under UV illumination 
and documented by Gel-Doc system. Gel photographs were 
analyzed by visual comparison of DNA fragments on base 
line and recurrent samples. 
2.6.3. Nested PCR-sequencing assay of PfATPase6
  We analyzed PfATPase6 S769N mutation, which was 
thought to be associated with artemisinin resistance[14,15],
among study isolates. The fragment of PfATPase6 in 
which S769N is located, was amplified by nested PCR 
method. The primary amplification was performed by 
using the oligonucleotide primers PfATPase6-P1, 5′-
TTTATTTTCATCTACCGCTATTGTATGTGG-3 ′  and 
PfATPase6-P2, 5′- GCATTTATACATCCTTCTCGTTAATCTA
AT-3′, as described elsewhere[20], in a reaction mixture of 
total volume 20 毺L which consisted of 3 毺L of genomic
DNA, 0.3 毺M of each primer pair, 0.2 mM of each 
deoxynucleoside triphosphate (dATP, dTTP, dGTP, dCTP),
2.5 mM MgCl2, PCR buffer, and 1.2 unit of Taq DNA 
Polymerase (Perkin Elmer, Branchburg, NJ, USA). 
Amplification was performed under the following conditions: 
initial denaturation at 94 曟 for 3 min, followed by 35 cycles 
of denaturation at 94 曟 for 45 sec, annealing at 46 曟 for
1 min, and extension at 72 曟 for 1 minute and a final 
extension period at 72 曟 for 10 min. The nested amplification 
was done by using the oligonucleotide primers PfATPase6-
N1, 5′-CACCTGTACAATCATCAAATAAGAAGG-3′ and 
PfATPase6-N2, 5′- CTTCTAATTTATAATAATCATCTGTAT
TC-3′, as described elsewhere[20], in a total volume 50 毺L
with similar reaction mixture described above and using 
primary product as template. Amplification was performed 
under the following conditions: initial denaturation at 94 曟 
for 3 min, followed by 35 cycles of denaturation at 94 曟 for 
1 min, annealing at 50 曟 for 1 min, and extension at 72 曟 
for 1 minute and a final extension period at 72 曟 for 10 min. 
Secondary PCR products were resolved by electrophoresis 
on 2% agarose gels and visualized by staining with ethidium 
bromide. Sequencing reactions were carried out with the ABI 
Prism Big Dye Terminator cycle sequencing ready reaction 
kit on a 3730 XL genetic analyzer (Perkin Elmer, Branchburg, 
NJ, USA) as specified by the manufacturer’s protocol. The 
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sequences of the amplicons were analyzed using the Bioedit 
Sequence Alignment Editor version 7.0.5.2. The sequences 
were then aligned using the online sequence alignment tool 
ClustalW (available at: http: //www.ebi.ac.uk/clustalw).
3. Results
3.1. In vivo therapeutic efficacy
  Patients were screened between October, 2010 and 
February, 2011 at the study site. A total of 2 176 patients 
with fever were screened for malarial parasite, of whom 351 
were positive for P. falciparum; 189 for Plasmodium vivax
(P. vivax); and 26 had mixed infections. Among the 351
P. falciparum cases, 207 patients were enrolled into the 
study and were randomized into two study arms. In AS+SP 
study arm 102 patients and in AM+LF study arm 105 patients 
were recruited (Figure 1). The demographic data and clinical 
parameters of the study groups are summarized in Table 1.
Total screen: 2176
Negative cases
1610
Pf cases
351
Pv cases
189
Mixed infection
26
Total enrolled
n=207
AS+SP
n=207
AM+LF
n=105
WTH: 3
LFU: 7
WTH: 5
LFU: 7
Evaluable by
Day 42
n=93
Evaluable by
Day 42
n=92
Figure 1. Profile of patients screened, enrolled and completing study 
protocol.
* WTH: Withdrawn, LFU: Loss to Follow-up.
  In AS+SP arm, out of 102 patients, three patients withdrew 
(one on day 1, one on day 2 and one on day 7) their consent 
from the study and seven patients were lost to follow-up 
due to movement away from site and could not be traced. 
End point was reached in 92 cases. No treatment failure 
case was recorded, so all the cases were classified as ACPR. 
Therefore, cure rate of AS+SP by per protocol analysis was 
100% (95% CI 96.1 - 100.0) (Figure 2). 
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Figure 2. PCR uncorrected and PCR corrected cure rates by per 
protocol analysis.
  In AM+LF arm, out of 105 recruited patients, five patients 
withdrew (three on day 1 and two on day 7) their consent, 
seven patients were lost to follow-up due to movement 
away from the site and 93 cases completed 42 days follow-
up. Out of 93, one patient came back with fever and asexual 
form of P. falciparum was detected on day 26. The msp-1 
and msp-2 genotyping of the treatment failure case showed 
that the recurring parasitaemia was due to recrudescence. 
Therefore, PCR corrected cure rate of AM+LF was 98.9% (95% 
CI 94.2 - 100.0) (Figure 2). 
  Statistical software “R” (version 2.13.1) was used for two 
sample tests for proportion. Both the combinations were 
highly effective and no significant difference was observed 
between the efficacy of AS+SP and AM+LF (Z = 0.997, P = 
0.159).
3.2. Analysis of PfATPase6 mutation
  The complete DNA sequence of the PfATPase6 gene is 
4 049-basepairs (bp), and it is located in chromosome 1. 
The gene contains three exons and three introns. A 1 793-
bp fragment spanning the coding region of exon 1 of the 
PfATPase6 gene was amplified by primary PCR. In the 
nested reaction, a 645-bp fragment was amplified from 
the primary amplicon which contain the S769N codon. The 
nested PCR products were then sequenced. 
  Out of 207 isolates, 100 samples (50 samples of AS+SP arm 
and 50 samples of AM+LF arm) were targeted for sequencing 
assay which were successfully performed in 92 isolates (45 
in AS+SP arm and 47 in AM+LF arm). No S769N mutation was 
detected in any of the analyzed samples (Figure 3).
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Figure 3. Sequencing image of nested PCR product indicating the 
polymorphism at codon 769 of PfATPase6 gene.
4. Discussion
  Due to the increasing CQ resistance of P. falciparum 
reported by different studies from various parts of the 
country[10], Government of India has included ACT (AS+SP) 
in National Drug Policy for treatment of all uncomplicated 
P. falciparum in 2010. Previously AS+SP was used in all 
primary health centers (PHCs) of 117 high risk districts 
and 256 chloroquine resistant PHCs of 48 districts for the 
treatment of falciparum malaria. Before the introduction of 
AS+SP, CQ resistant P. falciparum cases were treated by SP 
as the second line of treatment. However, SP resistance has 
developed quickly in other parts of the world following its 
widespread use[21-24]. During 2001-2007, twenty two studies 
were conducted in different parts of India and recorded SP 
failure rate 0.0%-56.7% with a median of 13.6%[25]. As SP is 
the partner drug of the recommended ACT, so the periodical 
monitoring of this combination will be helpful. Government 
of India has recently approved another ACT, AM+LF, for 
marketing but has not included in the National Drug Policy. 
AM+LF is a fixed dose combination and frequently used by 
private practitioners since 2006. 
  In this study, we found that both the combinations were 
well tolerated and produced rapid parasite and fever 
clearance. Majority of patients of both the study arms were 
free of parasites within 48 hours and cure rates were very 
high at the study site where chloroquine resistance is high 
(66%)[26]. The AS+SP combination was 100% effective against 
P. falciparum malaria. Studies from other parts of the 
country showed 0%-4% failure rate with this combination[25]. 
A recent study by Calcutta School of Tropical Medicine 
recorded a significant failure rate (9.5%) of AS + SP in 
Jalpaiguri district of the same state (unpublished data). 
Although the failure rate was just below the limit (10%) for 
drug policy change but it is alarming. So, the efficacy of 
this combination varies in different geographical regions 
of the same country. In AM+LF combination, we observed a 
case of treatment failure on day 26, so therapeutic efficacy 
of this combination is 98.9%. Similar finding was reported 
from India[27]. By using nested PCR sequencing assay, no 
PfATPase6 S769N mutation was found in any P. falciparum 
isolates collected from the study area. The finding is 
consistent with the results of the in vivo efficacy study. 
However, single case of treatment failure may be due to 
inadequate blood levels due to low absorption or altered 
pharmacokinetics of the drug.
  Both the combinations of ACTs tested in this study were 
effective for the treatment of uncomplicated falciparum 
malaria in India. AM+LF might be an alternative choice to 
AS+SP to the policy makers, if needed. 
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Table 1
Baseline characteristics of the study patients.
StudyArms
Characteristics
Sex no. (%) Weight(kg) Age category no.
 (%)
Age(year) Temperature
(曟)
Haemoglobin
(g/dL)
Parasite  count
(no/毺L)
AS+SP
(n = 102)
Male:67 (67.7)
Female:35 (34.3)
47.9依12.3
(25-77)
95% CI: 45.51-50.29
5-15:   29 (28.4)
Adult: 73 (71.6)
30.3依15.2
(9-68)
95% CI: 27.35-33.25
37.8依0.21
(37.5-38.6)
95% CI: 37.76-37.84
11.84依1.46
(9.9-15.0)
95% CI: 11.56-12.12
8 469.0依15 259.2
(1 040-90 000)
95% CI: 5 507.72-11 430.28
AM+LF
(n = 105)
Male:62 (59.1)
F e m a l e :  4 3 
(40.9)
48.2依13.9
(17-77)
95% CI: 45.54-50.86
5-15:  35 (33.3)
Adult: 70 (66.7)
29.5依16.1
(6-63)
95% CI: 26.42-32.58
37.7依0.39
(37.5-40.0)
95% CI: 37.63-37.77
11.04依1.15
(8.5-14.0)
95% CI: 10.82-11.26
8 176.0依13 655.1
(1 000-80 000)
95%CI: 5 564.15-10 787.85
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